New eye drug shows promise in early safety trial for blinding disease

NCT ID NCT05643118

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This early-stage study tested a new drug called OLX10212 in 21 people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The main goal was to see if the eye injections are safe and tolerable. Researchers also looked for early signs that the drug might help improve vision.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary โ€” we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

wet macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • California Retina Consultants

    Santa Maria, California, 93434, United States

  • Ophthalmic Consultants of the Capital Region

    Troy, New York, 12180, United States

  • Texas Retina Consultants

    Bellaire, Texas, 77401, United States

  • The Retina Institute

    St Louis, Missouri, 63128, United States

  • University Retina

    Oak Forest, Illinois, 60452, United States